Total Funding
19
47
Total FundingSeries C raised
Growth Score
-3 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
44350
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics.
Victoria Smith, PH.D.: Chief Scientific OfficerPast Role: Amphivena Therapeutics, Chief Scientific Officer- Patric Chun, M.D.: Vice President Clinical Development
About the Company
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and
enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing.
It was founded in 2012 and is headquartered in South San Francisco, California.
